The role of targeted agents in the treatment of metastatic breast cancer

Breast Care

Volumn 5, Issue 3, 2010, Pages 134-141

  Bischoff, Joachim ^a   Ignatov, Atanas ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Anti angiogenesis; Antibody; Breast cancer, metastatic; Multitargeting; PARP inhibition

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BSI 201; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EVEROLIMUS; GEMCITABINE; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NAVELBINE; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; HAND FOOT SYNDROME; HUMAN; METASTASIS; MOLECULAR THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; REVIEW; RISK REDUCTION; STOMATITIS; TREATMENT RESPONSE;

EID: 77954510732     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000314996     Document Type: Review

References (46)

1. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
2. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL: Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27:4966-4972.
3. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG: Randomized, double-blind, placebocontrolled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (MBC): AVADO. J Clin Oncol 2008;26:abstr 1011.
4. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27:abstr 1005.
5. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
6. Brusky J, et al.: RIBBON-2: A randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 2009;69(suppl 24):abstr 42.
7. Fumoleau P, Greil R, Rayson D, Müller V, Barni S, Aleknavicius E, Tellez E, Wilson C, Miles D: Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel (D) vs. D + PL in 1st-line HER2- negative locally recurrent (LR) or metastatic breast cancer (MBC)). Clin Cancer Res 2008;69:abstr 903.
8. Schneider BP, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
9. Seymour L, Dajee D, Bezwoda WR: Tissue platelet derived-growth factor (PDGFR) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 1993;26:247-252.
10. Goswarni S, Sahai E, Wyckoff JB, et al.: Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005;65:5278-5283.
11. Barrios C, Liu M, Lee S, Vanlemmens L, Ferrero J, Tabei T, Pivot X, Iwata H, Aogi K, Brickman M, Zhang K, Kern K, Martin M: Phase III randomized trial of sunitinib (SU) vs. capecitabine (C) in patients (Pts) with previously treated HER2- negative advanced breast cancer (ABC). Cancer Res 2009;69(suppl 24):abstr 46.
12. Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Boudarde S, Jain M, Schwarztberg L: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administrated in combination with paclitaxel in patients with locally recurrent or metastatic breast cancer. San Antonio Breast Cancer Symposium 2009, oral presentation.
13. Baselga J, Roché H, Costa F, Segalla JGM, Pinczowski H, Ciruelos EM, Cabral Filho S, Gomez P, Van Eyll B, on behalf of the SOLTI-0701 study investigators: SOLTI-0701: A multinational doubleblind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo in combination with capecitabine in patients with locally advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2009, oral presentation.
14. Nofech-Mozes S, Trudeau M, Kahn H, et al.: Patterns of recurrence in the basal and non-basal subtypes of triple-negtive breast cancer. Breast Cancer Res Treat 2009;118:131-137.
15. Liedtke C, Mazouni C, Hess KR, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
16. Carey LA, Dees EC, Sawyer L, et al.: The triple negative paradox: primary tumor chemosensitivitiy of breast cancer subtypes. Clin Cancer Res 2007;13: 2329-2334.
17. Amé JC, Spenlehauer C, de Murcia G: The PARP superfamily. Bioessays 2004;26:882-893.
18. Lewis C, Low JA: Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2007;8:1051-1056.
19. O'Shaughnessy J, et al.: Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplation (G/C) in patients with metastatic triple negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009;27(suppl 18):793s, abstr 3.
20. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui- Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361: 123-134.
21. Tutt A, Robson M, Garber JE, et al.: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27(suppl 18):abstr CRA501.
22. Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357: 39-51.
23. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
24. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274.
25. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.
26. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
27. Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
28. Cameron D, Casey M, Press M, Lindquist D, et al.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-543.
29. Lin NU, Dieras V, Devchand P, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459.
30. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120-125.
31. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M: Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab based therapy. Oncologist 2006;11:318-324.
32. Pegram MD, Konecny GE, O'Callaghan C, et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
33. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
34. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J: Randomized study of lapatinib alone or in combination with trastuzumab in women with erbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-1130.
35. Blackwell KL, et al.: A randomized study of lapatinib (Tykerb® ) in combination with trastuzumab versus lapatinib monotherapy in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 2009;69(suppl): abstr 61.
36. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-328.
37. Cortés J, Baselga J, Petrella T, et al.: Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2 positive breast cancer. Proc Am Soc Clin Oncol 2009;abstr 1022.
38. Baselga J, Gelmon KA, Verma S, Wardley A, Conte PF, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-1144.
39. Berns K, et al.: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402.
40. Lu C-H, Wyszomierski SL, Tseng LM, et al.: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5661-5662.
41. Fasolo A, Gianni L, Rorive A, et al.: Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2 overexpressing metastatic breast cancer with prior resistance to trastuzumab. Cancer Res 2009;69:abstr 406.
42. Gail D, Phillips L, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res 2008;68:9280-9290.
43. Vogel CL, Burris HA, Limentani S, et al.: A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2 positive MBC: final results. Proc Am Soc Clin Oncol 2009;abstr 1017.
44. Rabindran SK, Discafani CM, Rosfjord EC, et al.: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-3965.
45. Wong KK, Francasso PM, Bukowski RM, et al.: A phase I study with neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552-2558.
46. Burstein HJ, Sun Y, Tan AR, et al.: Neratinib (HKI-272), an irreversible pan erbB receptor tyrosin kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. San Antonio Breast Cancer Symposium 2008;abstr 37.